BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37728667)

  • 21. Diagnostic Value of 68Ga PSMA-11 PET/CT Imaging of Brain Tumors-Preliminary Analysis.
    Sasikumar A; Joy A; Pillai MR; Nanabala R; Anees K M; Jayaprakash PG; Madhavan J; Nair S
    Clin Nucl Med; 2017 Jan; 42(1):e41-e48. PubMed ID: 27846000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic performance and prognostic value of preoperative
    Chen S; Zhao Y; Tang Q; Wu C; Wang A; Ma L; Zhang X; Chen J; Gao Y; Liao X; Feng N; Fan Y; Zhang J; Li X; Liu M
    Cancer Imaging; 2022 Nov; 22(1):65. PubMed ID: 36435856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Head-to-Head Comparison of [
    Wegen S; van Heek L; Linde P; Claus K; Akuamoa-Boateng D; Baues C; Sharma SJ; Schomäcker K; Fischer T; Roth KS; Klußmann JP; Marnitz S; Drzezga A; Kobe C
    Mol Imaging Biol; 2022 Dec; 24(6):986-994. PubMed ID: 35771317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The roles of 68 Ga-PSMA PET/CT and 18 F-FDG PET/CT imaging in patients with triple-negative breast cancer and the association of tissue PSMA and claudin 1, 4, and 7 levels with PET findings.
    Arslan E; Ergül N; Beyhan E; Erol Fenercioglu Ö; Sahin R; Cin M; Battal Havare S; Can Trabulus FD; Mermut Ö; Akbas S; Fikret Çermik T
    Nucl Med Commun; 2023 Apr; 44(4):284-290. PubMed ID: 36756767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Special issue "The advance of solid tumor research in China": 68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma.
    Li Y; Zheng R; Zhang Y; Huang C; Tian L; Liu R; Liu Y; Zhang Z; Han H; Zhou F; He L; Dong P
    Int J Cancer; 2023 Jan; 152(1):42-50. PubMed ID: 35751420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of [
    Chen H; Pang Y; Li J; Kang F; Xu W; Meng T; Shang Q; Zhao J; Guan Y; Wu H; Xie F; Wang J; Sun L
    Eur Radiol; 2023 Feb; 33(2):1329-1341. PubMed ID: 35976396
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Parghane RV; Basu S
    J Nucl Med Technol; 2023 Sep; 51(3):261-262. PubMed ID: 36041875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The potential utility of [
    Lan L; Liu H; Wang Y; Deng J; Peng D; Feng Y; Wang L; Chen Y; Qiu L
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):963-979. PubMed ID: 34410435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of [
    Miao Y; Feng R; Guo R; Huang X; Hai W; Li J; Yu T; Qu Q; Zhang M; Shangguan C; Mi J; Zhu Z; Li B
    Eur Radiol; 2023 Jun; 33(6):4355-4366. PubMed ID: 36522509
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Dendl K; Koerber SA; Finck R; Mokoala KMG; Staudinger F; Schillings L; Heger U; Röhrich M; Kratochwil C; Sathekge M; Jäger D; Debus J; Haberkorn U; Giesel FL
    Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):4089-4100. PubMed ID: 34050777
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Qi Z; Yao X; Su M; Huang R
    Hell J Nucl Med; 2023; 26(2):155-156. PubMed ID: 37527052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the role of 18 F-fluorodeoxyglucose PET/computed tomography and 68 Ga-labeled FAP inhibitor-04 PET/CT in patients with malignant mesothelioma.
    Güzel Y; Kömek H; Can C; Kaplan İ; Kepenek F; Ebinç S; Büyükdeniz MP; Gündoğan C; Oruç Z
    Nucl Med Commun; 2023 Jul; 44(7):631-639. PubMed ID: 37114422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Superiority of [
    Fu L; Huang S; Wu H; Dong Y; Xie F; Wu R; Zhou K; Tang G; Zhou W
    Eur Radiol; 2022 Sep; 32(9):6281-6290. PubMed ID: 35380229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue.
    Krishnaraju VS; Kumar R; Mittal BR; Sharma V; Singh H; Nada R; Bal A; Rohilla M; Singh H; Rana SS
    Eur Radiol; 2021 Apr; 31(4):2199-2208. PubMed ID: 33001304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The performance of
    Jiang Y; Wen B; Li C; Tian Y; Xiao Z; Xu K; Xing D; Yu Z; Huang J; Jia J; He Y
    Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2114-2126. PubMed ID: 36808001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using
    Pang Y; Zhao L; Meng T; Xu W; Lin Q; Wu H; Zhang J; Chen X; Sun L; Chen H
    J Nucl Med; 2023 Mar; 64(3):386-394. PubMed ID: 36215571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual targeting PET tracer [
    Wang R; Jakobsson V; Wang J; Zhao T; Peng X; Li B; Xue J; Liang N; Zhu Z; Chen X; Zhang J
    Theranostics; 2023; 13(9):2979-2992. PubMed ID: 37284441
    [No Abstract]   [Full Text] [Related]  

  • 38. 68Ga-PSMA PET/CT Detecting Metastatic Lesion of RCC: Missed on 18F-FDG PET/CT.
    Jha S; Hemrom A; Shamim SA; Barwad A; Batra A
    Clin Nucl Med; 2023 Jun; 48(6):e294-e296. PubMed ID: 37133514
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Wang H; Zhu W; Ren S; Kong Y; Huang Q; Zhao J; Guan Y; Jia H; Chen J; Lu L; Xie F; Qin L
    Front Oncol; 2021; 11():693640. PubMed ID: 34249748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDG PET/CT and CT Findings of Renal Cell Carcinoma With Sarcomatoid Differentiation.
    Zhu H; Zhao S; Zuo C; Ren F
    AJR Am J Roentgenol; 2020 Sep; 215(3):645-651. PubMed ID: 32755159
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.